News for BiomX Inc. (PHGE.TA)

BiomX Inc. (PHGE), a clinical-stage company focused on phage therapies that target specific pathogenic bacteria, announced Monday positive, topline safety and efficacy results from its Phase 2 trial evaluating BX211 for diabetic foot osteomyelitis or DFO.

**media[581154]**

Net Loss: $17.7 million for 2024, a significant improvement from the $26.2 million loss in the previous year.Cash Position: Ended 2024 with $18.0 million in ca

**media[575685]**

**media[571268]**

BiomX Inc. (NYSE:PHGE) Q3 2024 Earnings Conference Call November 14, 2024 8:00 AM ETCompany ParticipantsMarina Wolfson – Chief Financial OfficerJonathan...

The following slide deck was published by BiomX Inc.

**media[465882]**

**media[463917]**

Biomx stock plunges to 52-week low, hits $0.87

**media[436916]**

GAITHERSBURG, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) (

Cash Balance: $32.7 million as of June 30, 2024, compared to $30.7 million as of June 30, 2023.Research and Development Expenses: $6.9 million for Q2 2024, up

Aug 15, 2024 / 12:00PM GMTOperator Greetings, and welcome to BiomX second quarter 2024 financial results conference call. (Operator Instructions) As a reminder,

BiomX Inc. (NYSE:NYSE:PHGE) Q2 2024 Earnings Call Transcript August 15, 2024 8:00 AM ETCompany ParticipantsMarina Wolfson - CFOJonathan Solomon -...

According to DelveInsight’s analysis, the market for cystic fibrosis is anticipated to increase during the forecast period (2024–2034), owing to the launch...

Shares of Patterson Companies, Inc. (NASDAQ: PDCO) moved lower during Wednesday’s session after the company reported worse-than-expected second-quarter financial results and lowered FY24 adjusted EPS guidance below estimates.

/PRNewswire/ -- The microbiomes market report has been published by Technavio. Market growth is estimated to accelerate at a CAGR of 21.95% and register an...

Gainers